People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rivus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $223.5M | $415.9M | 2019 |
| Aravive, Inc. | — | Biotechnology | Series C | $156.1M | $702.2M | 2013 |
| Minerva Neurosciences, Inc. | — | Biotechnology | Series B | $52.0M | $219.4M | 2015 |
| Normoxys, Inc. | — | Biotechnology | Series B | $25.3M | $23.8M | 2009 |
Francesco De Rubertis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Francesco De Rubertis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michele Ollier | 2 | 4 |
| Kevin Johnson | 1 | 12 |
| Srinivas Akkaraju | 1 | 10 |
| Patrick Enright | 1 | 10 |
| Mark Levine | 1 | 9 |
| David Clark | 1 | 8 |
| Anthony Sun | 1 | 8 |
| Derek DiRocco | 1 | 7 |
| MICHAEL DYBBS | 1 | 5 |
| Jeffrey Cleland | 1 | 4 |
| Shahzad Malik | 1 | 4 |
| Marc Beer | 1 | 4 |
| Ian Smith | 1 | 4 |
| Michael W. Rogers | 1 | 4 |
| Jay Shepard | 1 | 3 |
| Erin Lavelle | 1 | 3 |
| Joshua Brumm | 1 | 2 |
| David Kupfer | 1 | 2 |
| Jean-Pierre Garnier | 1 | 2 |
| Martin Tolar | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.